Ingalls Snyder buys $50,811,804 stake in Omeros Corporation (OMER)

Omeros Corporation (OMER) : Ingalls Snyder scooped up 349,773 additional shares in Omeros Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 4,414,579 shares of Omeros Corporation which is valued at $50,811,804.Omeros Corporation makes up approximately 2.86% of Ingalls Snyder’s portfolio.

Other Hedge Funds, Including , Perceptive Advisors sold out all of its stake in OMER during the most recent quarter. The investment firm sold 200,000 shares of OMER which is valued $2,302,000. Hap Trading sold out all of its stake in OMER during the most recent quarter. The investment firm sold 35,610 shares of OMER which is valued $445,125. Gsa Capital Partners Llp added OMER to its portfolio by purchasing 72,400 company shares during the most recent quarter which is valued at $905,000. Omeros Corporation makes up approx 0.05% of Gsa Capital Partners Llp’s portfolio. Financial Architects Inc added OMER to its portfolio by purchasing 400 company shares during the most recent quarter which is valued at $4,476.

Omeros Corporation opened for trading at $11.27 and hit $11.35 on the upside on Tuesday, eventually ending the session at $11.26, with a gain of 0.36% or 0.04 points. The heightened volatility saw the trading volume jump to 2,08,571 shares. Company has a market cap of $442 M.

On the company’s financial health, Omeros Corporation reported $-0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.49. The company had revenue of $10.00 million for the quarter, compared to analysts expectations of $9.44 million. The company’s revenue was up 212.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.

Many Wall Street Analysts have commented on Omeros Corporation. Shares were Reiterated by Maxim Group on Aug 10, 2016 to “Buy” and Lowered the Price Target to $ 19 from a previous price target of $30 .Maxim Group Initiated Omeros Corporation on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $21.Cantor Fitzgerald Initiated Omeros Corporation on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $21.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.

Leave a Reply

Omeros Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omeros Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.